Current state of #ALK testing based on Flatiron data Clinical Lung Cancer. ALK testing increased from 2011 to 2019 from 33% to 73%. Use of FISH dropped from 68% to 32% and use of NGS rose from <1% to 52%. Blood testing at 28% in 2019. #LCSM

clinical-lung-cancer.com/article/S1525-…

A case report just published Clinical Lung Cancer

A novel PRKAR1A::MET fusion responing to crizotinib in a patient with unresectable lung cancer

Learn more: bit.ly/3esAx2H

Immune-related myelitis is rare, but it can lead to significant morbidity.

A case report published Clinical Lung Cancer suggests that the combination of upfront IVIg with steroids is a reasonable treatment option for immune-related myelitis.

Learn more: bit.ly/3VokTWm

A new case report published Clinical Lung Cancer

U.S. FDA analysis of newly identified adverse events with #Lurbinectedin : Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome

Learn more: bit.ly/3SPLKso

MET is an actionable biomarker in NSCLC

A new review article on MET alterations in NSCLC published Clinical Lung Cancer

Asian Thoracic Oncology Research Group Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

bit.ly/3LZINUb

Report Clinical Lung Cancer describes rate of pneumonitis among patients with limited stage #SCLC treated with chemoradiation. Pooled risk of G3+ pneumonitis was 3-6%. Helpful reference as we anticipate several IO studies in this space.

clinical-lung-cancer.com/article/S1525-…

In a retrospective study of 68 patients with pN1 limited-stage small-cell lung cancer treated at Shanghai Chest Hospital, treatment outcomes after surgical resection were examined. The 2- and 5-year overall survival rates were 55.9% and 33.7%.

Read more: bit.ly/3fn9WEc

Outcome of patients with resected early-stage NSCLC and EGFR mutations: Results from the IFCT biomarkers France study

In resected stage I–II NSCLC, #EGFR mutations were found in 12.9% of cases, which had no significant impact on DFS and OS.

Read more: bit.ly/3BIiWvh

Just out Clinical Lung Cancer!

First-line #pembrolizumab in metastatic NSCLC with MET exon 14 skipping mutation and PD-L1 ≥50% (GFPC 01-20 study)

The obective response rate was 43% (14% complete response) with duration of response 13.9 months.

Learn more: bit.ly/3BpQMER

Cardiopulmonary toxicity following intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for stage III NSCLC, suggesting IMPT is a safe and efficacious treatment option with modern planning techniques

Read more: bit.ly/3qJCbze

Comprehensive review of immunotherapy in advanced NSCLC without driver mutations: availble therapeutic alternatives after progression and future treatment options

Authored by Dr. Jose Luis Leal and Dr. A/Prof Tom John.

Learn more: bit.ly/3BgDYAK

A case report describing ALK-rearranged NSCLC transforming to an ALK-rearranged inflammatory myofibroblastic tumor (IMT) upon recurrence. A common origin was suggested based on molecular profiling. A response was seen with ALK-TKI therapy. #LCSM

More: bit.ly/3DgBDIv

What is the role of TP53 co-mutation on EGFR-TKI efficacy?

A study published Clinical Lung Cancer suggests that diverse types of TP53 mutations may have a different impact on the prognosis of EGFR-mutant NSCLC. #LCSM

Find out more: bit.ly/3qb94o4

The decision to resume ICI after irAEs remains challenging.

In a restropective study of patients with stage IV NSCLC, rechallenge was associated with a relative high risk of second ≥G2 irAEs. The risk was less if the initial irAEs were resolved.

bit.ly/3pMACjv

Intraocular metastasis from lung cancer can lead to significant morbidity.

A systematic review and pooled analysis published Clinical Lung Cancer indicates that systemic therapy can be effective, especially when targeted therapy is feasible.

Learn more: bit.ly/3pBA7J0

ABLATE is a multicenter, randomized phase II study assessing whether the addition of SBRT to #lazertinib improves outcomes for patients with newly diagnosed EGFR-mutant NSCLC.

Link to the full article: bit.ly/3dLMW0W

#LCSM

Retrospective analysis of patients with advanced NSCLC treated across 12 Australian sites explored efficay and tolerability of the #IMpower150 regimen (atezolizumab, bevacizumab, platinum doublet chemotherapy) in oncogene driven tumors and CNS metastases.

bit.ly/3pw7Ljr

Hodgkin lymphoma survivors have a higher risk of lung cancer development.

In a study using the SEER database, 862 of 56,856 HL survivors developed lung cancer (incidence rate: 157 per 100,000 person-years). Predictors included male, older age, and RT.

bit.ly/3wF5c2H